Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Bik promotes proteasomal degradation to control low-grade inflammation
Yohannes A. Mebratu, … , Scott Randell, Yohannes Tesfaigzi
Yohannes A. Mebratu, … , Scott Randell, Yohannes Tesfaigzi
Published December 19, 2023
Citation Information: J Clin Invest. 2024;134(4):e170594. https://doi.org/10.1172/JCI170594.
View: Text | PDF
Research Article Inflammation

Bik promotes proteasomal degradation to control low-grade inflammation

  • Text
  • PDF
Abstract

Although chronic low-grade inflammation does not cause immediate clinical symptoms, over the longer term, it can enhance other insults or age-dependent damage to organ systems and thereby contribute to age-related disorders, such as respiratory disorders, heart disease, metabolic disorders, autoimmunity, and cancer. However, the molecular mechanisms governing low-level inflammation are largely unknown. We discovered that Bcl-2–interacting killer (Bik) deficiency causes low-level inflammation even at baseline and the development of spontaneous emphysema in female but not male mice. Similarly, a single nucleotide polymorphism that reduced Bik levels was associated with increased inflammation and enhanced decline in lung function in humans. Transgenic expression of Bik in the airways of Bik-deficient mice inhibited allergen- or LPS-induced lung inflammation and reversed emphysema in female mice. Bik deficiency increased nuclear but not cytosolic p65 levels because Bik, by modifying the BH4 domain of Bcl-2, interacted with regulatory particle non-ATPase 1 (RPN1) and RPN2 and enhanced proteasomal degradation of nuclear proteins. Bik deficiency increased inflammation primarily in females because Bcl-2 and Bik levels were reduced in lung tissues and airway cells of female compared with male mice. Therefore, controlling low-grade inflammation by modifying the unappreciated role of Bik and Bcl-2 in facilitating proteasomal degradation of nuclear proteins may be crucial in treating chronic age-related diseases.

Authors

Yohannes A. Mebratu, Jane T. Jones, Congjian Liu, Zerihun H. Negasi, Mizanur Rahman, Joselyn Rojas-Quintero, George T. O’Connor, Wei Gao, Josée Dupuis, Michael H. Cho, Augusto A. Litonjua, Scott Randell, Yohannes Tesfaigzi

×

Figure 4

The BH3 domain of Bik inhibits nuclear p65–induced transcriptional activity.

Options: View larger image (or click on image) Download as PowerPoint
The BH3 domain of Bik inhibits nuclear p65–induced transcriptional activ...
A549 NF-κB luciferase reporter cells were infected with either Ad GFP, Ad-Bik, or Ad-BikL61G (mutant Bik that does not kill cells) and subsequently treated with 10 ng/ml TNF-α for 6 hours. (A) Protein lysates were analyzed for the expression of Bik by Western blotting. (B) Percentages of viable cells were analyzed by trypan blue exclusion assay. n = 3. Cells were infected with the adenoviral vectors at MOIs indicated below the bar. (C) NF-κB transcriptional activity was analyzed in the cell lysates. n = 4. (D) Percentages of cells expressing nuclear p65 were analyzed by immunofluorescent staining. n = 6–8; N = 2. (E) A549 NF-κB luciferase reporter cells were treated with vehicle, TAT, or TAT-BikL61G peptides for 2 hours and subsequently treated with TNF-α for 6 hours. NF-κB transcriptional activity was analyzed in the cell lysates. n = 3. (F) A549 cells were treated with 10 μM control peptides or BikL61G peptides for 2 hours, followed by treatments with 10 ng/ml TNF-α for the indicated times in the presence of phosphormide. Cell lysates were analyzed for the level of IκBα protein by Western blotting. (G) Cytosolic-protein lysates from bik+/+ and bik–/– MAECs were analyzed for levels of phospho- and total IκBα by Western blotting. (H) Cytosolic lysates from bik+/+ and bik–/– MAECs were immunoprecipitated using anti-p65 antibody and analyzed for IκBα levels by Western blotting. (I) Cytosolic and nuclear fractions of lysates from bik+/+ and bik–/– MAECs were analyzed for levels of p65 and IκBα by Western blotting. (J) Nuclear fractions of lysates isolated from bik+/+ and bik–/– MAECs analyzed for levels of p65 and p50 by Western blotting. (K) HAECs transfected with siControl or IRF-1 siRNA. Western blot of nuclear lysates for Bik and p65 protein. (L) bik–/– mice instilled with 50 μg HDM intranasally daily for 5 consecutive days and on days 6 and 7 intranasally treated with 10 μM of control TAT peptide, BH3 WT Bik peptide, or BH3 mutant Bik peptide. BAL fluids analyzed for inflammatory cell numbers. n = 4–6/group. Two-tailed Student’s t test was used to compare between 2 groups, and grouped results were analyzed using 2-way ANOVA. Data are represented as mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts